Liquid biopsy & ctDNA diagnostics
Detecting and quantifying circulating tumour DNA (ctDNA) in blood for companion oncology diagnostics and minimal-residual-disease (MRD) monitoring, replacing or supplementing tissue biopsy.
How it works
This is a procurement category, not a named manufacturer's product. As a paid service, Bioecon finds suppliers for your task, agrees configuration and specification, and arranges supply; the price is on request. Bioecon may receive a fee from suppliers — this is disclosed and does not affect the portal's grades or lists.
Technology
Liquid biopsy & ctDNA diagnostics — Evidence, registration route, funding and suppliers are on the technology page.
Blood-based detection and quantification of circulating tumor DNA (ctDNA) for cancer companion diagnostics and molecular residual disease (MRD) monitoring, replacing or supplementing tissue biopsy — led by Guardant Health, Natera and Foundation Medicine in the US, Sysmex Inostics in the EU, …
Links
- Import and registration route
- SERV — — (operator: Rosprirodnadzor, Rostechnadzor)
- Capabilities
- Testing & analytics
Related items
Other categories for this technology
Laboratory & analytical instruments · Reagents & kits
In the same node
Allelopathic crops · Aquaculture microbiome management · Automated ELISA analyzers · BECCS · Bio-content certification & mass-balance traceability (ISCC PLUS, USDA BioPreferred) · Bio-flotation reagents for mining · Bio-integrated DAC (hybrid bio-DAC) · Bio-mining (phytoremediation, tailings valorization) · All →